Positive family history increases likelihood of visual field loss at presentation

Article

Patients with a positive family history of glaucoma are 10 times as likely to have visual field (VF) defects at the time of their diagnosis, according to a study published in the April issue of Clinical & Experimental Ophthalmology, the official Journal of the Royal Australian and New Zealand College of Ophthalmologists.

Patients with a positive family history of glaucoma are 10 times as likely to have visual field (VF) defects at the time of their diagnosis, according to a study published in the April issue of Clinical & Experimental Ophthalmology, the official Journal of the Royal Australian and New Zealand College of Ophthalmologists.

Narme C. Deva MBChB of the Department of Ophthalmology, University of Auckland, New Zealand and colleagues conducted the case-control study of 107 newly diagnosed glaucoma patients to identify risk factors associated with VF loss on first presentation of glaucoma. VF grading included classifications for nasal step, paracentral scotoma and/or arcuate scotoma.

Thirty seven percent of patients had a positive family history. Mean patient age was 59 years; mean IOP, 21.4 mmHg; mean cup:disc ratio, 0.69. The mean age of patients presenting without VF defects was 54 years, compared with a mean age of 63 years for patients presenting with mild to severe VF defects. At presentation, 29% of patients scored ≥6 on the Advanced Glaucoma Intervention Study (AGIS) scale. Multivariate logistic regression analysis identified independent risk factors for VF loss at presentation: positive family history (odds ratio, 10.43) and age (odds ratio, 1.15).

The researchers concluded that, as a positive family history is associated with a ten times increased risk of VF defect at presentation, early identification of these higher-risk patients could prevent extensive VF loss.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.